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Abstract 26 
 27 
The current lack of an accurate, cost-effective and non-invasive test that would allow for 28 
screening and diagnosis of gynaecological carcinomas, such as endometrial and ovarian cancer, 29 
signals the necessity for alternative approaches. The potential of spectroscopic techniques in 30 
disease investigation and diagnosis has been previously demonstrated. Here, we used 31 
attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy to analyse 32 
urine samples from women with endometrial (n=10) and ovarian cancer (n=10), as well as from 33 
healthy individuals (n=10). After applying multivariate analysis and classification algorithms, 34 
biomarkers of disease were pointed out and high levels of accuracy were achieved for both 35 
endometrial (95% sensitivity, 100% specificity; accuracy: 95%) and ovarian cancer (100% 36 
sensitivity, 96.3% specificity; accuracy 100%). The efficacy of this approach, in combination 37 
with the non-invasive method for urine collection, suggest a potential diagnostic tool for 38 
endometrial and ovarian cancers.  39 
 40 
 41 
 42 
 43 
 44 
 45 
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1. Introduction 49 
 50 
Endometrial and ovarian cancers are the commonest cancers in post-menopausal 51 
women worldwide. In the UK alone, 9,300 women develop endometrial cancer, of whom 2,100 52 
die annually 1; ovarian cancer affects 7,300 women resulting in 4,100 deaths per year (i.e., 53 
~40% overall survival) 2. The epidemiology of endometrial and ovarian cancer is closely 54 
entwined, histological subtypes of endometrial cancer mirror subtypes found in ovarian cancer 55 
and the same risk factors seem to influence both diseases 3. Endometrial cancer is often 56 
symptomatic at an early stage (stage I) when there is still time for treatment 4. In the case of 57 
ovarian carcinoma, however, symptoms present late in most cases and after the cancer has 58 
already metastasized within the abdomen, resulting in late-stage disease and poor prognoses 5. 59 
An accurate and early diagnosis of both diseases, and especially ovarian cancer, is of major 60 
need as it would permit an early intervention and potentially early-stage diagnosis and 61 
consequently improved prognosis. 62 
The gold standard for diagnosis of endometrial cancer is biopsy performed either in an 63 
outpatient or inpatient setting after a patient presents with symptomatic bleeding. For ovarian 64 
cancer diagnosis in patients with symptoms, women initially undergo a pelvic examination, 65 
followed by measurement of serum cancer antigen (CA-125); if symptoms persist in the 66 
absence of raised CA-125 levels, an abdominal and transvaginal ultrasound follow 5. In 67 
asymptomatic women for ovarian cancer screening, a combination of these biomarkers is used. 68 
In the future, with the escalating incidence of endometrial cancer secondary to obesity, there 69 
might be a role for screening for disease. All of the above-mentioned diagnostic approaches 70 
have drawbacks, either being invasive (e.g., biopsy) or expensive (e.g., ultrasound). Even 71 
though a blood biomarker would be an ideal diagnostic approach, CA-125 has now been found 72 
to be unsuitable for early-stage diagnosis as it is only elevated in 50% of the individuals 6. A 73 
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number of research groups are actively investigating the utility of multiple biomarkers for a 74 
more accurate diagnosis of endometrial and ovarian cancers 6, 7. However, current methods of 75 
biomarker identification are heavily dependent on multiplex assays and molecular techniques 76 
which are costly. 77 
Vibrational spectroscopy has gained increasing attention in the recent years due to its 78 
potential as a diagnostic tool for various diseases, by providing chemical and structural 79 
information of the sample in use 8, 9. Both infrared (IR) and Raman spectroscopic techniques 80 
have been extensively used for cancer diagnostics using tissue, cells or biofluids, such as blood 81 
plasma/serum, urine, bile, ascitic fluid and cerebrospinal fluid 10, 11. A screening or diagnostic 82 
test should be non-invasive to facilitate compliance and, as such, venepuncture and urine 83 
analysis are ideal. Blood- and urine-based spectroscopy have already been applied successfully 84 
in studies including brain 12, breast 13, gynaecological 14, 15  and other types of cancer. In the 85 
present study, attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy 86 
was used to analyse urine samples from women with endometrial and ovarian cancer and 87 
facilitate towards their segregation form healthy controls. The classification models that were 88 
employed to distinguish between these groups were partial least squares discriminant analysis 89 
(PLS-DA), principal component analysis with support vector machines (PCA-SVM) and 90 
genetic algorithm with linear discriminant analysis (GA-LDA). 91 
2. Materials and Methods 92 
 93 
2.1 Study population and sample collection 94 
 95 
 All samples were collected at Royal Preston Hospital UK after obtaining ethical 96 
approval (16/EE/0010). All experiments were performed in accordance with relevant laws and 97 
guidelines, and approved by the ethics committee at University of Central Lancashire (UCLan). 98 
Informed consent was obtained from all human subjects. Urine samples were collected from 99 
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30 individuals: 10 healthy women with no symptoms of cancer who were used as controls, 10 100 
women with endometrial cancer and 10 women with ovarian cancer. All urine specimens were 101 
obtained after patients were administered a general anaesthetic prior to hysterectomy for benign 102 
or malignant indications. All patients had undergone a period of at least 6 hours fasting; the 103 
suggested preoperative fasting time is 6-8 hours for light meals and 2 hours for fluids 16, 17. 104 
Prolonged fasting (12-16 h) should be avoided as it triggers gluconeogenesis precipitation and 105 
increases the organic response to trauma 18. Specimens were obtained after aseptic preparation 106 
of the urethra and after catheterisation, thus avoiding any contamination.  All cases were staged 107 
according to the guidelines by the International Federation of Gynecologic Oncology (FIGO). 108 
Samples were kept at -80°C until the time of spectroscopic analysis. Before analysis, all 109 
samples were left to thaw at room temperature and 50 μl were deposited on low-emissivity 110 
(low-E) slides (MirrIR Low-E slides, Kevley Technologies, USA); they were then left to air-111 
dry for approximately 45 minutes. All urines were taken pre-operatively on the day of surgery 112 
in both controls and disease patients and patients had not received any treatment for the disease 113 
prior to surgery. All endometrial and ovarian cancers were high grade cancers. Sub-group 114 
analysis for other incidental diseases or factors such as type 2 diabetes, hypertension or 115 
medication was not performed in this study. 116 
2.2 Spectroscopic analysis  117 
 118 
ATR-FTIR spectroscopy was employed for the analysis of the urine samples. A Tensor 119 
27 FTIR spectrometer with a Helios ATR attachment (Bruker Optics Ltd, Coventry, UK) which 120 
contained a diamond crystal, was used for the data collection. The OPUS 7.2 software was used 121 
for spectral acquisition. Spectral resolution was set at 8 cm-1 and mirror velocity at 2.2 kHz; 32 122 
scans were acquired for each spectrum for optimal signal-to-noise ratio. The diamond crystal 123 
was cleaned with distilled water after the use of each sample and a background spectrum was 124 
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collected to eliminate atmospheric changes. A CCTV camera was used for visualisation and 125 
navigation across the sample’s surface; ten spectra were acquired from different locations of 126 
each sample to minimize bias. 127 
2.3 Data analysis  128 
After collection, the raw spectra need to be pre-processed in order to account for 129 
inconsistencies relating to the experimental procedure and spectral acquisition. Pre-processing 130 
and computational analysis of the data was performed using PLS Toolbox version 7.9.3 131 
(Eigenvector Research, Inc., Manson, USA) and an in-house developed IRootLab toolbox 132 
(http://trevisanj.github.io/irootlab/) 19. For the purposes of this study, raw spectra were initially 133 
pre-processed as following: cut to the bio-fingerprint region (1800-900 cm-1), rubberband 134 
baseline corrected and vector normalised. Rubberband baseline correction is used to correct 135 
underlying oscillations on the baseline of the spectra which can be caused by scattering effects, 136 
reflection, temperature, concentration, among other instrumental anomalies that render 137 
wavenumbers, known for having no absorption, with absorbance values different from zero 20. 138 
For further classification spectra were divided into training (60%, n = 18 patients) and 139 
test (40%, n = 12 patients) sets using the Kennard-Stone sample selection algorithm 21. Partial 140 
least squares discriminant analysis (PLS-DA), principal component analysis with support 141 
vector machines (PCA-SVM) and genetic algorithm with linear discriminant analysis (GA-142 
LDA) were used as classification methods. PLS-DA is a linear classification technique that 143 
uses partial least squares (PLS) to find a straight line that divide the classes spaces 22. PCA-144 
SVM makes use of principal component analysis (PCA) 23 for data compression; the PCA 145 
scores are then used as input variables for a support vector machine (SVM) classifier 24. The 146 
SVM classifier was based on a radial basis function (RBF) kernel which is used to transfer the 147 
data to a feature space by means of a non-linear discriminant criterion; a linear decision surface 148 
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is then constructed in this feature space to separate the classes analysed 25. Both PLS-DA and 149 
PCA-SVM were optimized using cross-validation venetian blinds in a “leave one patient out” 150 
fashion (10 splits with 1 sample per split). GA-LDA was optimized using an external validation 151 
data set having half of the samples of the test set. The algorithm was applied three times, using 152 
100 generations with 200 chromosomes, and the best model was selected. Crossover and 153 
mutation probabilities were set to 60% and 10%, respectively. 154 
 In order to study the differences at specific wavenumbers, we implemented a simple 155 
approach, namely difference-between-means (D-B-M) spectra, which subtracts the mean 156 
spectra from a reference class (i.e., healthy controls). A peak-detecting algorithm was then used 157 
to denote six of the most differentiating peaks. 158 
2.4 Availability of data 159 
 160 
 All data (raw and pre-processed spectra) along with appropriate code identifiers have 161 
been uploaded onto the publicly accessible data repository Figshare 162 
(https://figshare.com/articles/Potential_of_mid-infrared_spectroscopy_as_a_non-163 
invasive_diagnostic_test_for_endometrial_or_ovarian_cancer_in_urine/5929516).  164 
2.5 Statistical analysis 165 
 166 
The classification performance of the chemometric algorithms was evaluated according 167 
to the accuracy, sensitivity and specificity on the test set. The accuracy (AC) represents the 168 
number of samples correctly classified considering true and false negatives; sensitivity (SENS) 169 
and specificity (SPEC) measure the proportion of positives and negatives that are correctly 170 
identified, respectively 26. These parameters are calculated as follows: 171 
AC(%) = (
TP+TN
TP+FP+TN+FN
) × 100         (3) 172 
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SENS(%) = (
TP
TP+FN
) × 100           (4) 173 
SPEC(%) = (
TN
TN+FP
) × 100          (5) 174 
where TP stands for true positive, TN for true negative, FP for false positive and FN for false 175 
negative. 176 
The peaks that were responsible for the differentiation after the D-B-M spectra 177 
approach, were imported into GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, 178 
92037, USA) to conduct statistical analyses and calculate the P-values. Differences between 179 
the two groups (i.e., healthy vs cancer) were assessed using a Student’s t-test (two-tailed, non-180 
parametric, Mann-Whitney test, 95% confidence interval). The data were expressed as the 181 
mean ± standard deviation (SD). A P-value of 0.05 or less was considered significant. 182 
3. Results 183 
3.1 Segregation between cancer patients and controls 184 
 185 
All spectra were pre-processed before comparison of the cancer patients with the 186 
healthy controls. Supplementary Fig. 1A shows the average pre-processed spectra for each 187 
class. The most discriminatory peaks for the comparison between endometrial cancer and 188 
healthy women were: 1593 cm-1 (P <0.0001, 95% CI = -0.0179 to -0.012), 1508 cm-1 (P 189 
<0.0001, 95% CI = 0.0038 to 0.0103), 1462 cm-1 (P <0.0001, 95% CI = -0.0115 to -0.0058), 190 
1400 cm-1 (P <0.0001, 95% CI = 0.0107 to 0.0161), 1335 cm-1 (P <0.0001, 95% CI = 0.0053 191 
to 0.0093), 1041 cm-1 (P <0.0001, 95% CI = 0.0063 to 0.0118) (Supplementary Fig. 1B). Fig. 192 
1 shows the differences in the absorbance of the above-mentioned peaks; a general increase 193 
was denoted in the endometrial cancer patients with the exception of the peaks at 1593 cm-1 194 
and 1462 cm-1 which showed decreased levels. The means and SD values for these peaks were: 195 
1593 cm-1 (mean/SD for healthy: 0.18/0.011; mean/SD for cancer: 0.164/0.0098), 1508 cm-1 196 
(mean/SD for healthy: 0.0445/0.0115; mean/SD for cancer: 0.0506/0.0104), 1462 cm-1 197 
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(mean/SD for healthy: 0.0958/0.0151; mean/SD for cancer: 0.0833/0.0064), 1400 cm-1 198 
(mean/SD for healthy: 0.0509/0.007; mean/SD for cancer: 0.0645/0.0095), 1335 cm-1 199 
(mean/SD for healthy: 0.0237/0.0053; mean/SD for cancer: 0.0315/0.007), 1041 cm-1 200 
(mean/SD for healthy: 0.0286/0.0083; mean/SD for cancer: 0.0383/0.0109). 201 
The peaks responsible for differentiation between healthy and ovarian cancer patients 202 
were: 1597 cm-1 (P <0.0001, 95% CI = -0.0173 to -0.0114), 1508 cm-1 (P <0.0001, 95% CI = 203 
0.0038 to 0.0103), 1408 cm-1 (P <0.0001, 95% CI = 0.0102 to 0.0149), 1373 cm-1 (P <0.0001, 204 
95% CI = 0.0076 to 0.0122), 1231 cm-1 (P <0.0001, 95% CI = 0.0042 to 0.0074), 1041 cm-1 (P 205 
<0.0001, 95% CI = 0.0063 to 0.0118) (Supplementary Fig. 1B). Similarly, to endometrial 206 
cancer, the majority of the peaks showed increased absorbance when cancer was present, apart 207 
from the peak at 1597 cm-1 (Fig. 2). Means and SD values for each of the abovementioned 208 
peaks were: 1597 cm-1 (mean/SD for healthy: 0.18/0.0104; mean/SD for cancer: 0.166/0.0098), 209 
1508 cm-1 (mean/SD for healthy: 0.0445/0.0115; mean/SD for cancer: 0.0506/0.0104), 1408 210 
cm-1 (mean/SD for healthy: 0.0548/0.0067; mean/SD for cancer: 0.0676/0.0085), 1373 cm-1 211 
(mean/SD for healthy: 0.0326/0.0075; mean/SD for cancer: 0.0427/0.0085), 1231 cm-1 212 
(mean/SD for healthy: 0.0198/0.0079; mean/SD for cancer: 0.0256/0.0079), 1041 cm-1 213 
(mean/SD for healthy: 0.0286/0.0083; mean/SD for cancer: 0.0383/0.0109). 214 
3.1 Classification algorithms to calculate diagnostic accuracy 215 
All classification algorithms (PLS-DA, PCA-SVM and GA-LDA) were applied to the 216 
data after the same pre-processing (cut to the bio-fingerprint region [1800-900 cm-1], 217 
rubberband baseline correction and vector normalisation). 218 
PLS-DA was employed to differentiate healthy, endometrial and ovarian cancer 219 
samples using 10 latent variables (LVs), accounting for 96.02% of cumulative variance (Fig. 220 
3A). The number of LVs was selected according to the lowest error of cross-validation (15.4% 221 
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for healthy; 16.2% for endometrial cancer; and 12.5% for ovarian cancer) and maximum 222 
explained variance (96.02%). PLS-DA loadings are shown in Fig. 3B, where the first three LVs 223 
have higher coefficients at ~1041 cm-1, ~1082 cm-1, ~1462 cm-1, ~1547 cm-1, ~1589 cm-1 and 224 
~1670 cm-1. The predicted classes for each sample spectrum analysed by PLS-DA are shown 225 
in Fig. 3C (healthy), 3D (endometrial cancer) and 3E (ovarian cancer), where a degree of 226 
superposition is observed among the three classes. Only the ovarian cancer dataset showed 227 
clearer separation from the other two classes. 228 
 PCA-SVM was performed using 10 principal components (PCs), accounting for 229 
97.33% of cumulative variance (Fig. 4A). The PCA loadings (Fig. 4B) had higher coefficients 230 
in regions very similar to PLS-DA: ~1042 cm-1, ~1090 cm-1, ~1130 cm-1, ~1462 cm-1, ~1508 231 
cm-1, ~1543 cm-1, ~1589 cm-1 and ~1667 cm-1. The predicted classes for each sample are shown 232 
in Fig. 4C (healthy), 4D (endometrial cancer) and 4E (ovarian cancer). In comparison to PLS-233 
DA, Fig. 4 C-E shows a clearer separation among the classes, with only a few samples being 234 
misclassified. 235 
 GA-LDA classified healthy, endometrial and ovarian cancer with a fitness of 1.53 (Fig. 236 
5A). The GA-LDA discriminant function (DF) plot for the three classes is shown in Fig. 5B 237 
with clear segregation between the three classes. A total of 20 variables showed differences 238 
between the three classes: 922 cm-1, 972 cm-1, 1007 cm-1, 1011 cm-1, 1018 cm-1, 1045 cm-1, 239 
1049 cm-1, 1061 cm-1, 1084 cm-1, 1265 cm-1, 1362 cm-1, 1366 cm-1, 1400 cm-1, 1412 cm-1, 1500 240 
cm-1, 1535 cm-1, 1562 cm-1, 1566 cm-1, 1682 cm-1 and 1716 cm-1 (Fig. 5B). 241 
 Table 1 shows the classification rates achieved by the three algorithms, with PCA-SVM 242 
being superior. Both accuracy and sensitivity values for PCA-SVM model ranged from 92.5% 243 
(healthy) to 100% (ovarian cancer); and specificity ranged from 96.3% (ovarian cancer) to 244 
100% (endometrial cancer). GA-LDA had accuracy ranging from 90.0% (endometrial cancer) 245 
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to 98.3% (ovarian cancer); sensitivity ranging from 70.0% (endometrial cancer) to 100% 246 
(healthy/ovarian cancer); and specificity ranging from 87.5% (healthy) to 100% (endometrial 247 
cancer). PLS-DA was the worst model as only the ovarian cancer data set had quality 248 
parameters as good as the other algorithms. Accuracy ranged from 57.5% (endometrial cancer) 249 
to 92.5% (ovarian cancer); sensitivity ranged from 62.5% (endometrial cancer) to 87.5% 250 
(ovarian cancer); and specificity ranged from 86.3% (healthy) to 90% (ovarian cancer). The 251 
classification rates for the training and test sets using all three algorithms are shown in 252 
Supplementary Table 1. 253 
4. Discussion 254 
 255 
The wavenumbers that were mostly responsible for segregation between the different 256 
classes could facilitate as potential diagnostic biomarkers. In endometrial cancer patients the 257 
majority of the IR bands, associated with proteins and nucleic acids, were increased in 258 
comparison to healthy individuals. This could potentially be due to an elevated concentration 259 
of biomolecules, previously suggested as biomarkers for endometrial cancer, such as human 260 
epididymis protein 4 (HE4), CA-125 or carcinoembryonic antigen (CEA) 7, 27, 28; the increased 261 
level of nucleic acid may be caused by the unconstrained proliferation of cells. Only two out 262 
of the six discriminatory peaks were lower in the cancer cases; these were attributed to C-C 263 
vibrations of phenyl rings of proteins (~1593 cm-1, Amide II) and CH2 vibrations of lipids 264 
(~1462 cm-1). These results could be potentially explained by a number of possible reasons. 265 
For instance, preceding research has demonstrated a simultaneous increased degradation of 266 
proteins as well as a decreased protein synthesis during cancer cachexia 29. Another study 267 
demonstrated decreased expression of follicle-stimulating hormone (FSH) in endometrial 268 
cancer patients when these were compared to healthy controls 30. The same study also showed 269 
decreased levels of matrix metalloproteinases (MMP), which is a family of enzymes implicated 270 
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in normal and pathological processes, and previously suggested as novel biomarkers and/or 271 
therapeutic targets in human cancer 31. Also, apolipoprotein-1 (ApoA-1), prealbumin (TTR) 272 
have also been shown to be decreased in endometrial cancer patients 7. 273 
With regards to the decrease in the lipid region of endometrial cancer cases, previous 274 
work may again justify the results of the current study. After studying a number of lipids in 275 
urine, Skotland et. al revealed that increased and/or decreased levels of molecular lipids could 276 
be used as non-invasive biomarkers for prostate cancer with high levels of diagnostic accuracy. 277 
Therefore, similar conclusions could possibly be extrapolated to endometrial cancer 32. 278 
Previous research has also suggested that lipids, and specifically cholesterol, were lower in 279 
blood samples of endometrial cancer than controls 33; this might explain the lower absorbance 280 
in the lipid region (~1462 cm-1) of endometrial cancer patients. More recent studies have further 281 
confirmed the increased risk of low cholesterol concentration in other types of cancer as well, 282 
such as lung, prostate or colon 34, 35. 283 
When we compared ovarian cancer patients with healthy controls, the discriminatory 284 
peaks were mainly attributed to proteins and nucleic acids. Increased levels of these 285 
biomolecules were observed in cancerous samples with an exemption of a peak 1597 cm-1 286 
which was assigned to C-C phenyl ring of proteins. Continuous research has previously shown 287 
that a cancer biomarker can be either upregulated or downregulated. After reviewing several 288 
biomarkers, a total of 111 were found significantly altered between ovarian cancer and controls, 289 
with ~60% of them being elevated in cancer and ~40% decreased 36. Some of the biomarkers 290 
showing lower levels in cancerous state are, for instance, ApoA-1, FSH, microtubule-291 
associated protein 1 light chain 3 (LC3) and epidermal growth factor receptor (EGFR) 6, 37, 38. 292 
Therefore, this may explain the observed decrease in the Amide II region. On the contrary, 293 
increased peaks could potentially be attributed to other established biomarkers such as HE4, 294 
previously found to be increased in urine samples of ovarian cancer patients, CA-125, cancer 295 
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antigen 15-3 (CA15-3) and others 6, 39. A relatively recent study, also demonstrated increased 296 
levels of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) when urine samples from 297 
ovarian cancer patients were analysed 40. 298 
 Three classification algorithms were employed to calculate the diagnostic accuracy 299 
with which spectroscopy identified endometrial and ovarian cancer. The optimal approach was 300 
PCA-SVM which identified endometrial cancer with 95% sensitivity and 100% specificity 301 
(95% accuracy) and ovarian cancer with 100% sensitivity and 96.3% specificity (100% 302 
accuracy), which are exceptionally high in comparison to conventional molecular and imaging 303 
methods. 304 
Previously, numerous studies have investigated blood biomarkers as a relatively non-305 
invasive approach towards diagnosis of endometrial cancer. A study using serum HE4 yielded 306 
sensitivity of 45.4% and 95% sensitivity 41; another study developing a multimarker panel for 307 
the early detection of endometrial cancer suggested that prolactin could be used as an accurate 308 
biomarker with sensitivity and specificity of ~98% 30 . Combination of three different 309 
biomarkers (ApoA-1, prealbumin and transferrin) distinguished normal samples from early-310 
stage endometrial cancers with 71% sensitivity and 88% specificity, as well as normal samples 311 
from late-stage cancer with 82% sensitivity and 86% specificity 7. After reviewing 13 studies, 312 
Timmermans et. al., showed that ultrasonography achieved sensitivity and specificity of 90-313 
98% and 35-54%, respectively 42. Magnetic resonance imaging (MRI) has been shown to detect 314 
early and advanced endometrial cancer with high sensitivity (87-100%) and specificity (90-315 
99%) but stage Ic and stage II disease had significantly reduced sensitivity (19-56%) whereas 316 
specificity remained high (86-96%) 43.  317 
Currently, molecular tests measuring serum CA-125 for ovarian cancer, achieve 318 
sensitivity of only 50-60% for early-stage disease and specificity of >95% 6, 44. Moreover, 319 
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transvaginal ultrasound (TVS), computed tomography (CT), MRI and power Doppler are of 320 
high-cost and achieve sensitivity <90% for early ovarian cases and relatively high false positive 321 
results which render them less useful for screening 6. Combination of different biomarkers has 322 
been shown to achieve higher sensitivity and specificity values. For example, two combinations 323 
of serum biomarkers for ovarian cancer are CA-125, CA 72-4, CA 15-3 and macrophage 324 
colony-stimulating factor (M-CSF) 45, as well as CA-125, ApoA-1, a truncated form of 325 
transthyretin and a cleavage fragment of inter-alpha-trypsin inhibitor heavy chain H4 46; the 326 
above-mentioned combinations of biomarkers improved sensitivity and specificity to 70-73% 327 
and 97-98%, respectively. Even though the improved accuracy is acceptable, there is still room 328 
for improvement. A different study found that a blood-based assay of 11 analytes could 329 
distinguish ovarian cancer from benign case with sensitivity and specificity of 90% 37. 330 
However, an important drawback of molecular methods is their expense and laborious sample 331 
preparation and analysis, in contrast to spectroscopic methods which are rapid and label-free. 332 
5. Conclusion 333 
 334 
This pilot study demonstrates the efficacy of ATR-FTIR spectroscopy in detecting 335 
endometrial and ovarian cancers in urine samples, with high levels of accuracy. Being rapid, 336 
non-destructive and at the same time cost-effective, spectroscopy is introduced as an ideal 337 
method for studying these types of cancer and could potentially be translated into clinical 338 
practise in the future as either a screening or diagnostic test. An adequately powered study will 339 
be required to demonstrate the true diagnostic accuracy and validate these preliminary results. 340 
Furthermore, the quick and non-invasive nature of urine collection and subsequent analysis has 341 
the potential of a preferable vehicle for repeated measurements, thus facilitating monitoring of 342 
disease progression/regression/recurrence or even therapeutic response. 343 
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 441 
Figure Legends 442 
 443 
Figure 1: Analysis of the top six discriminatory peaks between healthy controls and 444 
endometrial cancer patients. 445 
Figure 2: Analysis of the top six discriminatory peaks between healthy controls and ovarian 446 
cancer patients. 447 
Figure 3: Cumulative explained variance using PLS-DA (A); PLS-DA loadings on LV1, 2 and 448 
3 (B); predicted healthy class versus endometrial and ovarian cancer (C); predicted endometrial 449 
cancer class versus healthy and ovarian cancer (D); predicted ovarian cancer class versus 450 
healthy and endometrial cancer (E). Class measured 1 = healthy control; 2 = endometrial 451 
cancer; 3 = ovarian cancer. LV: Latent Variable. 452 
Figure 4: Cumulative explained variance using PCA (A); PCA loadings on PC1, 2 and 3 (B); 453 
predicted probability of healthy class versus endometrial and ovarian cancer (C); predicted 454 
probability of endometrial cancer class versus healthy and ovarian cancer (D); predicted 455 
probability of ovarian cancer class versus healthy and endometrial cancer (E). Class measured 456 
1 = healthy control; 2 = endometrial cancer; 3 = ovarian cancer. PC: Principal Component. 457 
Figure 5: Fitness function (A); Discriminant Function (DF) plot (B); and selected variables by 458 
GA-LDA (C). 459 
